Karuna Therapeutics stock trades steady as Bristol Myers acquisition closes and schizophrenia program advances

Karuna Therapeutics stock is now tied directly to Bristol Myers Squibb after the large-cap biopharmaceutical group completed its acquisition of Karuna Therapeutics Inc. (ISIN US5011311096), bringing the KarXT schizophrenia franchise into its central nervous system pipeline. The deal, first announced in late 2023, positioned Karuna Therapeutics as a strategic asset for Bristol Myers Squibb, with investors continuing to watch regulatory and clinical milestones for KarXT as the key value drivers. Although Karuna shares are no longer independently quoted on Nasdaq following completion of the transaction, historical market metrics and the deal valuation continue to frame how the combined company and its shareholders view the asset.

Acquisition at about $14 billion valuation

The core anchor for Karuna Therapeutics stock from an investor perspective is the acquisition valuation agreed with Bristol Myers Squibb. According to Bristol Myers Squibb’s transaction announcement in December 2023, the company agreed to acquire Karuna Therapeutics in an all-cash deal valuing Karuna at approximately $14 billion, based on a purchase price of $330 per Karuna share. This price represented a substantial premium to Karuna Therapeutics’ pre-announcement trading level of roughly $160 per share earlier in 2023, illustrating the strategic importance Bristol Myers Squibb attached to the KarXT program. The premium therefore approached about 106%, highlighting how centrally KarXT’s late-stage data influenced the valuation and providing a historical benchmark for how the asset was priced by a major pharmaceutical buyer.

Before the transaction announcement, Karuna Therapeutics stock had already experienced meaningful appreciation driven by clinical data from KarXT in schizophrenia. In 2022, Karuna reported Phase 3 trial results showing statistically significant improvement in schizophrenia symptoms compared with placebo, which had helped lift the company’s market capitalization from around $3 billion in early 2022 to well over $5 billion by mid-2023. The definitive $14 billion takeout price thus more than doubled the mid-2023 implied equity value and demonstrated Bristol Myers Squibb’s confidence in both the addressable market for schizophrenia and the differentiation profile of KarXT as a muscarinic receptor modulator.

Revenue and R&D context around KarXT

While Karuna Therapeutics had not yet generated commercial product revenue prior to the acquisition, its financial statements still provide relevant fundamental metrics for investors assessing how Bristol Myers Squibb will integrate the business. In Karuna’s last reported full fiscal year before the buyout, the company disclosed net losses of several hundred million dollars, driven largely by research and development expenses for KarXT and other pipeline programs. For example, Karuna’s R&D spending in fiscal 2023 exceeded $300 million, up from a little over $200 million in fiscal 2022, reflecting the shift from mid-stage to late-stage clinical development and preparation for regulatory submissions. This year-on-year increase of more than $100 million, or roughly 50%, demonstrates how rapidly development costs can ramp as a program approaches commercialization.

Operating expenses also rose in line with the company’s growth, including investments in manufacturing scale-up and commercial planning for KarXT. As Karuna approached the regulatory filing phase, it guided that cash and cash equivalents at the end of fiscal 2023 were sufficient to fund operations into at least late 2025 on a stand-alone basis. However, Bristol Myers Squibb’s acquisition changed that trajectory, providing the financial backing of a large biopharmaceutical company with annual revenues above $40 billion and robust free cash flow. The deal implies that Bristol Myers Squibb expects KarXT and related programs eventually to contribute material revenue, with potential peak sales scenarios often discussed in the market in the multi-billion dollar range over time, although those projections remain subject to regulatory and competitive developments.

KarXT schizophrenia program as main product

KarXT, Karuna’s lead product candidate, is an oral combination of xanomeline and trospium designed to target muscarinic receptors in the central nervous system while limiting peripheral side effects. The program has focused initially on treating adults with schizophrenia, a condition affecting millions of people globally and characterized by positive symptoms such as hallucinations and delusions, negative symptoms such as social withdrawal, and cognitive deficits. In late-stage trials, KarXT demonstrated meaningful improvements on standard schizophrenia rating scales compared with placebo, without the same degree of dopaminergic side effects seen with many existing antipsychotics.

The data set for KarXT has supported regulatory interactions with the US Food and Drug Administration (FDA), and Bristol Myers Squibb has indicated that it plans to continue advancing KarXT through the regulatory process, including supplemental studies and potential label expansion into adjunctive therapy or other indications such as psychosis in Alzheimer’s disease. For investors, the commercial potential for KarXT in schizophrenia alone could be substantial given the large treated population and the need for better tolerated therapies. The integration of KarXT into Bristol Myers Squibb’s broader neuroscience strategy may also enable international launches over time, extending the revenue opportunity beyond the US market.

Stock and market backdrop after de-listing

From a stock-market perspective, Karuna Therapeutics had been listed on Nasdaq under the ticker KRTX before the acquisition, and its share price performance over the years reflected growing confidence in KarXT’s clinical profile. Over the twelve months leading up to the December 2023 deal announcement, Karuna Therapeutics stock traded in a wide range roughly between $150 and $250 per share, with volatility around data readouts and sector-wide sentiment toward small and mid-cap biotech companies. The agreed $330 per share cash consideration at signing therefore placed the takeout price near the high end of that historical range and above most contemporaneous analyst price targets.

Following completion of the acquisition, Karuna’s stand-alone stock ceased to trade, and former Karuna shareholders received cash from Bristol Myers Squibb in accordance with the merger terms. Today, investors who are interested in the trajectory of the KarXT program and the legacy Karuna Therapeutics asset must instead look at Bristol Myers Squibb stock, where the impact will be reflected in pipeline valuation and, over time, potential revenue contributions. Bristol Myers Squibb shares continue to trade on the New York Stock Exchange, and the market will monitor how KarXT’s regulatory and launch timeline influences overall earnings and guidance.

Read-more and investor resources

KarXT’s broader market potential

Beyond schizophrenia, KarXT’s mechanism of action has attracted interest for potential application in other psychiatric and neurological disorders. Muscarinic receptors play roles in cognition, mood, and psychosis, and KarXT’s approach of modulating these pathways could be relevant in conditions such as psychosis related to neurodegenerative diseases or treatment-resistant forms of schizophrenia. As Bristol Myers Squibb evaluates additional indications, the development program may expand, with new trials providing further data and potentially larger peak sales estimates if multiple indications are approved.

KarXT also sits within a broader trend of large pharmaceutical companies investing in neuroscience assets after years of relative underinvestment in central nervous system disorders. Successful commercialization would not only deliver revenue but could also support Bristol Myers Squibb’s positioning as a leader in psychiatric therapeutics, complementing its strengths in oncology, cardiovascular disease, and immunology. The valuation attached to Karuna Therapeutics in the acquisition reflects both current expectations for schizophrenia and optionality for further indications, which together underpin the long-term strategic rationale for the deal.

Fact box: Karuna listing history